Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4574 - LCZ 696, administered during doxorubicin, trastuzumab or pertuzumab treatment, prevents cardiotoxicity in our in vitro model

Date

11 Sep 2017

Session

Poster display session

Presenters

Nicola Maurea

Citation

Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367

Authors

N. Maurea1, R. Paciello2, G. Piscopo1, A. Rienzo1, G. Sorrentino1, C. Maurea1, R. Caputo3, M. De Laurentiis3, P. Maiolino4, C. Coppola1, C. De Lorenzo2

Author affiliations

  • 1 Division Of Cardiology, ISTITUTO NAZIONALE TUMORI – IRCCS – FONDAZIONE G. PASCALE, NAPLES, ITALY, 80131 - Napoli/IT
  • 2 Ceinge – Advanced Biotechnology S.c.ar.l., Department of Molecular Medicine and Medical Biotechnology, University ‘Federico II’, Naples, Italy, 80131 - Naples/IT
  • 3 Department Of Breast Surgery And Cancer Prevention, ISTITUTO NAZIONALE TUMORI – IRCCS – FONDAZIONE G. PASCALE, NAPLES, ITALY, 80131 - Napoli/IT
  • 4 Pharmacy, ISTITUTO NAZIONALE TUMORI – IRCCS – FONDAZIONE G. PASCALE, NAPLES, ITALY, 80131 - Napoli/IT
More

Resources

Abstract 4574

Background

Doxorubicin (DX), Trastuzumab (T) and Pertuzumab (P) are antineoplastic drugs used in the treatment of breast cancer. Adverse cardiovascular events related to anticancer drugs are among the leading causes of morbidity and mortality in cancer patients. Sacubitril-valsartan (LCZ 696) is a combination drug, made up of neprilysin inhibitor sacubitril and angiotensin II receptor blocker valsartan, used for the treatment of heart failure in patients with a reduced ejection fraction. Here, we aim to assess whether LCZ 696, administered during DX, T or P treatment, reduces in vitro anticancer drugs-related cardiotoxicity compared to Valsartan (V), used as a control drug.

Methods

The H9C2 rat cardiomyoblasts were seeded in 96-well plates at a density of 1 x 104 cells/well and incubated at 37 °C with 5% CO2 for 16 hours. After the addition of 200 nM of T, P or DX in the culture medium, cells were incubated for 72 hours. The cells were further treated in the absence or presence of 10 µM of LCZ 696 or V for additional 3 days. Viable cells were counted by trypan blue exclusion test and cell survival was expressed as percentage of viable cells compared to control untreated cells.

Results

LCZ 696 reduced significantly T, P and DX related toxicity in H9C2 cardiomyoblasts as evidenced by the higher percentage of viable cells treated with combinations of T, P or DX with LCZ 696 with respect to cells treated with T, P or DX alone (p 

Conclusions

LCZ 696, administered during DX, T or P treatment, significantly increases the viability of treated cells, thus reducing cardiotoxic effects of these drugs, as demonstrated by our in vitro experiments. The future perspective aims to test LCZ 696 in in vivo models to assess its capability to blunt left ventricular dysfunction after antineoplastic treatments.

Clinical trial identification

Legal entity responsible for the study

Nicola Maurea

Funding

None

Disclosure

M. De Laurentiis: Advisory Board: Novartis, Roche, Pfizer, AstraZeneca, Celgene, Eisai. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.